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Development of LANA transgenic mice. (A) The LANA transcription locus (14) and transgene construct carrying LacZneo (27) as previously 
described and the LANA transgene construct used here. SV40 pA, simian virus 40 poly A; b-geo, b-galactosidase-neomycin; TK, thymidine kinase. 
(B) Southern blot analysis of tail DNA, digested with BamHI and hybridized with a LANA-specific probe to reveal the founder-specific integration 
sites. Lane 1 shows the transgene plasmid as a positive control (Pos.), lane 5 contains the DNA from a C57BL/6 mouse as negative control (Neg.), 
and remaining lanes represent DNA from LANA transgenic animals belonging to lines i, ii, and iii (animals 4 and 6 are siblings). Arrowhead indi-
cates a fragment specific for all transgenic animals; other bands are integration-site specific. (C and D) Real-time quantitative RT-PCR analysis of 
spleen samples for LANA transgene mRNA or apoB housekeeping mRNA resolved on a 2% tris-borate-EDTA–agarose gel and (C) subsequent 
Southern blot analysis with a probe specific for LANA (LANA-P). Lanes i–v refer to spleen RNA from 5 different transgene-positive animals. NTC, 
nontemplate control; MW, 100-bp molecular weight marker. (D) Lanes 1–3 show transgene-negative, and lanes 4–6 transgene-positive, littermates 
after backcross into the C57BL/6 background.
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mice,  but  not  wild-type 
littermates, showed prom-
inent  PNA-positive  foci 
in  the  absence  of  immu-
nization (Figure 4). With 




KLH–immunized  (n  =  9) 
LANA transgenic mice. In 
contrast,  wild-type  mice 





































LANA expression in spleens. (A) Immunohistochemistry using a rat 
mAb against LANA (right panels) or rabbit polyclonal antibody against 
PCNA (left panels) and visualization with NovaRed (brown) and 
hematoxylin (blue) counterstain in a transgene-negative and a LANA-
positive animal. Arrowhead indicates the localization of LANA-positive 
cells. Magnification, ×400. (B) Diameter of LANA-positive foci for wild-
type and transgenic animals (P ≤ 0.01, n = 11). The box represents the 
interquartile range, the line within the box indicates the median and 
whiskers indicate the highest and lowest values.
Table 
Changes in B cell compartments in LANA transgenic mice
	 	 	 Wild	type	 	 	 LANA
Class	 Marker	 %	 SD	 n	 %	 SD	 n	 P
Mature IgM+IgD+CD19+ 13.62 4.00 6 20.06 6.09 26 0.05
Activated IgM+IgD+CD19+FSChi 4.35 0.98 6 7.05 1.60 26 0.0002
MZ IgM+IgD–CD19+ 6.09 2.33 6 4.84 1.70 26 0.25
MZ CD21+CD23–CD19+IgD– 1.16 0.70 4 2.11 0.99 25 0.06
FL CD21–CD23+CD19+IgD+ 3.61 4.59 4 10.30 4.56 25 0.05
GC CD21–CD23+CD19+IgD– 0.50 0.19 4 0.52 0.27 25 0.86
GC CD19+CD23+CD40+CD38– 7.44 3.18 4 4.35 3.69 23 0.15
Memory CD45R+IgG+CD27+ 9.33 1.32 5 8.65 3.17 25 0.45
Plasma CD45R+CD27–CD138+ 0.64 0.49 6 0.53 0.24 26 0.63
FL, follicular.
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Analysis of GC development in a representative LANA and littermate 
wild-type mouse. Markers are indicated on the left (No 1°, no primary 
antibody). All sections are counterstained blue with hematoxylin. Mag-
nification, ×400 (bottom 2 panels); ×100 (remaining panels).
Figure 
GC response to NP(30)-KLH. Spleen sections of wild-type and LANA transgenic mice with or with-
out NP(30)-KLH immunization (-I) were stained with PNA. Arrowheads indicate GCs. Magnification, 
×40 (top panels); ×100 (bottom panels).
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Anaplastic plasmacytoma in a LANA 
transgenic animal. (A–D) IgG-k 
expression (surface and intracellular) 
in a lymphoma from LANA transgen-
ic (A and C) and nontransgenic (B 
and D) littermates. (E and F) CXC-
chemokine receptor 4 (CXCR4) for 
expression in LANA transgenic (E) or 
control (F) mice. Magnification, ×100 
(A, B, E, and F); ×400 (C and D). All 
sections are counterstained blue with 
hematoxylin. (G and H) Flow cytom-
etry analysis of the anaplastic plas-
macytoma. (I and J) Flow cytometry 
analysis of spleen of a nontransgenic 
littermate. (G and I) Gates represent 
CD138+B220+CD27– lymphoma cells 
at 16% frequency and normal spleen 
cells at 3% frequency. (H and J) Gates 
represent IgG-k+B220–CD27– lym-
phoma cells at 20% frequency and nor 
mal spleen cells at 2% frequency.
Figure 6
H&E stain of wild-type mice and phenotypes in LANA transgenic mice 
— LPD, MZ lymphoma (MZ), and anaplastic plasmacytoma (PC). 
Arrowheads indicate individual cells that exemplify the phenotype in 
panels E, G, and H. Magnification, ×100 (A–D); ×400 (E–H).
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PCR analysis of VDJH and DJH rearrangements in tumors of LANA transgenic mice. Total spleen genomic DNAs were used in the PCR reactions 
analyzing tumors. (A–C) PCR analysis of total spleen genomic DNAs from 4 LANA transgenic mice with tumors, 2 C57BL/6 mice older than 300 
days (WT), and 2 different murine B cell lines resolved on a 1.5% Tris-acetate-EDTA–agarose gel, used as controls for the clonality. WT lanes 
demonstrate VDJH1, VDJH2, VDJH3, and VDJH4 rearrangements (A and B) using VH7183 (A) or VHJ558 primers (B) and DJH1, DJH2, DJH3, and 
DJH4 rearrangements (C) using Dq52 primers. The primers were designed to amplify all rearrangement products between JH4 and VH7183, VHJ558, 
or Dq52; 4 different bands would be expected by the combination of each primer set. M, 100-bp DNA Ladder (New England Biolabs Inc.) (D) DNA 
samples used for the Ig rearrangement PCRs were quantified using real-time quantitative PCR to demonstrate equal total DNA concentrations.
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